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1On behalf of my Cabinet colleagues, I am pleased to present the New Zealand Biotechnology Strategy,
which outlines the Government’s vision and direction for the development of biotechnology in New Zealand.
Biotechnology is an industry in itself, but it is much more than that; it is a sector generating biological
knowledge, skills and technology that can contribute in numerous ways to achieving our economic, social
and environmental aspirations.
The Royal Commission on Genetic Modification pointed to the 21st century as “the biotechnology century”
and recommended that New Zealand develop a biotechnology strategy. The Growth and Innovation
Framework, launched by the Prime Minister in February 2002, also recognises the importance of
biotechnology to New Zealand’s future. We want New Zealanders to participate in and benefit from the
development and innovation of this fast-moving technology sector. 
New Zealand is in a fortunate position. Our economy is built on an outstanding ability to add value to natural
resources by applying biological knowledge. We have world-class strengths in agriculture, forestry, animal 
and human health research, and forensic and environmental research, all of which involve biotechnology.
Emerging applications have the potential to transform many industries, using biological processes to
enhance the quality of life. Examples include improved diagnostics for human and animal health, pest
control, industrial processes with reduced waste streams and the development of biodegradable products.
We want to gain these benefits in a responsible way. The Royal Commission on Genetic Modification
emphasised “preserving opportunities” and “going forward with care”. No one pretends that wrestling 
with opportunities and challenges in a fast-moving and complex area is easy, but standing still is not an option.
This strategy is about development with care. Care comes from recognition that the biotechnology sector
will be strengthened by engagement with society, by building understanding on both sides of diverse
perspectives, and by having regard for ethical and cultural concerns. Care is also provided by robust
regulation that safeguards people and the environment.
The Biotechnology Sector Taskforce, set up under the Growth and Innovation Framework, has
highlighted important factors for commercial growth of New Zealand biotechnology. A growing
biotechnology sector depends on a deep and sophisticated knowledge, skill and research base; investment
and infrastructure that are based on our strengths and directed at commercialisation; and strong links
between research and industry in New Zealand and abroad to promote the uptake of biotechnology. 
At the core of the strategy is an ongoing commitment by the Government to work with people in
communities, researchers and industry, so New Zealanders together can achieve benefit from developing
and applying our world-class biological knowledge, skills and innovation.
Ministerial Foreword
Pete Hodgson
Minister of Research, Science and Technology
May 2003
LIVESTOCK HORTICULTURE DAIRY
What is Biotechnology?
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In a sense biotechnology has been with us for centuries. Broadly
defined, biotechnology is a term for a group of technologies that
are based on applying biological processes to solve problems and
make products. Nature itself is not static and humans have always
built on and enhanced biological processes. Traditional
biotechnologies include fermentation applications such as beer,
cheese, bread making and cosmetics, as well as animal and plant
breeding techniques.
It is the opportunities and challenges associated with the
development and application of modern biotechnology that are 
the main focus of this strategy. 
The term ‘modern biotechnology’ is used to describe recent
research and applications that relate to molecular and cellular
biology. It includes a range of techniques from microbiology and
biochemistry through to gene technology. 
Some people mistakenly think that biotechnology and genetic
engineering (GE) are the same thing. In fact GE, based on the
modification of genetic material, is only one aspect of gene
technology, which is itself a specific subset of modern
biotechnology. Examples of modern biotechnology and its uses 
in New Zealand are outlined throughout this strategy.
IN
T
R
O
D
U
C
T
IO
N
MEDICINE NATURAL PRODUCTS THE ENVIRONMENT
FORESTRY MARINE WINE
Vision, Goals and Policy Principles
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A Vision for Biotechnology in New Zealand
Three goals support the Government vision for biotechnology:
New Zealand responsibly develops
and applies our world-class
biological knowledge, skills,
innovation and technologies to
benefit the wealth, health and
environment of New Zealanders,
now and in the future.
Build understanding about
biotechnology and
constructive engagement
between people in the
community and the
biotechnology sector.
Grow New Zealand’s
biotechnology sector to
enhance economic and
community benefits.
Manage the development
and introduction of new
biotechnologies with a
regulatory system that
provides robust safeguards
and allows innovation.
4Vision, Goals and Policy Principles
Guiding Principles
Government biotechnology policy will be guided by a commitment to:
Benefit for New Zealand – Focus on outcomes from biotechnology that benefit
the wealth, health and environment of New Zealanders.
Sustainable development – Meet present needs without compromising future
generations, through integrating economic growth, social equity and
environmental and cultural well-being.
Responsibility and ethics – Responsible, ethical use and uptake of
biotechnology, in a way that safeguards the well-being of both people and the
environment, by effective identification and management of risks and uncertainty.
Innovation – Foster and encourage innovative biotechnology developments.
Partnership and participation – Work in partnership with the sector and involve
citizens in public policy and ethical issues, through open information and
participation processes that acknowledge diverse community interests.
Treaty of Waitangi – Work in partnership with appropriate Maori authorities to
empower Maori in development decisions that affect them and enable Maori to
participate so as benefit their economic, social and cultural well-being.
Biosecurity and biological diversity – Maintain biosecurity and protect
biological diversity, particularly that of New Zealand’s unique flora and fauna.
Why we need a Government strategy for biotechnology 
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The Royal Commission on Genetic
Modification (RCGM) recommended 
New Zealand develop a biotechnology
strategy “to ensure that New Zealand kept
abreast of developments in biotechnology,
and that these were used to national
advantage while preserving essential social,
cultural and environmental values”.
Subsequently, the Government, in its Growth
and Innovation Framework (GIF), has
identified biotechnology as one of three
enabling sectors critical to New Zealand’s
future, with wide applications across the
economy. (The other two sectors are
information and communications technology
and creative industries.) A Biotechnology
Sector Taskforce was set up as part of the GIF
work to specifically focus on the commercial
growth of the sector.
Biological knowledge already earns income
for the country through farming, horticulture,
fishing, forestry, industrial processes and
ecotourism. It also plays a leading role in
keeping our environment and people healthy.
Modern biotechnology provides opportunities
for New Zealand to build on our strong
biological base. The Government believes we
need to focus on fostering the development
and uptake of this enabling technology so it
can add value in a wide range of our
industries, through improving productivity
and generating new products and services.
New Zealand has the makings of a 
world-class centre for biotechnology
research. The Government believes we must
move to ensure we are equally smart about
using this research to derive benefits for 
New Zealand, as well as the rest of the world.
All emerging technologies throw up
challenges, and modern biotechnology
throws up more than most. The complexity
of some of the science can be challenging.
Some of the science and potential
applications challenge our understanding of
what it is to be human. There is a need to
establish clear values about our
responsibilities to wider society and the
environment. We also need to come to grips
with effective ways of managing risks and
uncertainty. 
Generating value from biotechnology is also
challenging. The commercialisation path from
discovery to tried and tested products,
particularly for bio-pharmaceuticals, can be
longer and more prone to failure than most
other areas of technology. Other countries
have benefits of scale and resources to push
their advantage with biotechnology.
These challenges are not a reason for
standing still or saying “it is all too hard”.
They are a reason for putting in place
processes and initiatives that will enable us to
tackle the challenges as we move forward.
This Biotechnology Strategy provides an
integrated approach to addressing the
opportunities and challenges presented by
this rapidly evolving technology - for realising
benefits in a responsible way. 
Why we need a Government strategy for biotechnology 
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Key themes from consultation
The strategy links key themes that have
emerged from extensive consultation and
public dialogue. The discussion has been
conducted in many forums, including
feedback on the strategy discussion
document released in October 2002,
deliberations of the Biotechnology Sector
Taskforce and the earlier consultations of
the RCGM and the former Independent
Biotechnology Advisory Council (IBAC).
The themes are:
 leadership and co-ordination
There is a need for greater long-term
certainty about the environment for
biotechnology in New Zealand. A clear
commitment to development and
assurance is seen as important. There was
a call for stronger co-ordination and
clearer leadership, both within the sector
and across government, to support the
integrated approach in the strategy
framework; 
 fostering community awareness of
and engagement in biotechnology
There is a need for easily accessible,
independent information about new
biotechnology developments, and for
informed debate and dialogue. A
challenge for the New Zealand
biotechnology sector will be to work with
different groups in the community to
discuss and address issues and concerns
and thereby earn their confidence as
consumers and investors;
 harnessing New Zealand’s
biotechnology strengths and the
contribution of the sector to our
economic, social and environmental
well-being
A partnership between industry and
government is seen as a key to
progressing development of the sector for
the well-being of the community. 
The sector itself is seen as needing to be
more proactive about growing and using
our current biotechnology strengths in
agriculture, horticulture, forestry and
biomedicine; strengthening clusters and
networks; increasing the uptake and
transfer of research into products and
services of value; and promoting 
New Zealand biotechnology under a
national branding approach.
The Government is seen as a facilitator,
building capability and infrastructure,
funding fundamental research,
encouraging development investment,
fostering global linkages and ensuring a
workable regulatory regime.
A linked theme that emerged is the need
for decisions on biotechnology
development and use to enhance and
support other government goals,
especially sustainable development, public
health priorities and environmental
management, including biodiversity and
biosecurity.
7 managing risks and having regard for
ethical, cultural and innovation
dimensions 
Consultation indicated a growing
pragmatism about biotechnology. People
recognise that biological knowledge and
skills have been a key feature of our
economy in the past and will be in the
future. While some are opposed to the
use of genetically engineered products
outside laboratories, many others are
open to case-by-case assessment and risk
management approaches to new
biotechnology. 
Trust in a rigorous regulatory system and
well signposted opportunities for input into
public policy issues, ethical and cultural
matters are regarded as important. At the
same time it was strongly suggested that
regulatory and consultation processes be
designed and conducted in ways that do
not stifle innovation;
 fostering Maori participation in
biotechnology research and
commercial development
A recurring theme in the consultation is
the importance of Maori participation in
biotechnology research and commercial
development. Aspects that were
highlighted are: 
 Maori have much to offer and much to
gain from biotechnology. As tangata
whenua they have a major interest in,
and deep knowledge of, natural
resources and primary sector industries
that are strongly connected with
biotechnology;
 the scientific community must take a
lead in constructively interacting with
Maori at all stages of biotechnology
development, with an emphasis on
consultation early in the research
process;
 incorporating knowledge of
Matauranga Maori and Maori 
culture is seen as a part of building
New Zealand’s science capacity; 
 Maori leadership is seen as important in
encouraging knowledge of science. In
particular there is value seen in building
a body of Maori scientists and using
them to strengthen science
programmes aimed at Maori in schools,
and to encourage and provide
mentoring for young Maori scientists;
 recognition of Maori collective
approaches to indigenous knowledge
and intellectual property and resolution
of the WAI 262 claim were identified as
issues to be addressed. 
Reviews of other countries’ biotechnology strategies
especially Australia, Canada, UK and Singapore
Working papers on futurewatch, auditing
regulation for investment in public research
Post RCGM policy work
Consultation on Biotechnology
Strategy discussion paper
Growth & Innovation
Framework
Biotechnology Sector
Taskforce Report
Biotechnology Strategy
Royal Commission on Genetic
Modification
This strategy statement is also complemented by a wide range of background and supporting material, as indicated below.
Much of this material can be accessed via the Ministry of Research, Science and Technology web page; www.morst.govt.nz.
8Case Study
Maurice Wilkins – third man of DNA
The story of the DNA double helix has become part of our scientific folklore – and 
New Zealander Maurice Wilkins was a key figure in those exciting times.
Maurice Wilkins was born in the isolated Wairarapa community of Pongaroa in 1916. 
He gained a physics degree from St John’s College, Cambridge, in 1938 and soon began
work on radar for the war effort. With this expertise he was moved to the Manhattan 
Project, an American wartime initiative that ultimately saw the deployment of two nuclear
bombs. This experience made Maurice Wilkins a vocal opponent of nuclear weapons. 
Wilkins instead began working on the application of X-ray crystallography to biology. He
devised a method that allowed the long and fragile molecules of DNA to be pulled out
parallel to each other, so that the photographs showed their actual shapes. These patterns,
taken in collaboration with Rosalind Franklin, alerted James Watson and Francis Crick to
the possibility that DNA was helical. After several false starts, this allowed Watson and
Crick to build their correct model of the structure of DNA. 
Finally, on 25 April 1953, in one of the truly defining moments of 20th century science,
three papers juxtaposed in the science journal Nature detailed the structure of DNA. The
implications of this discovery were at least as great as those that led to the atomic bomb–
but in a far more positive way. In 1962, Wilkins, Watson and Crick received the Nobel Prize
in Physiology or Medicine for this discovery.
Now 86, Maurice Wilkins lives in London, where he continues to teach at King’s College
and is currently completing his biography.
Strategy Approach
This strategy is about development with
care. Care comes from recognition that the
biotechnology sector will be strengthened by
engagement with society, building
understanding on both sides of diverse
perspectives, and by having regard for
ethical and cultural concerns. Care is also
provided by robust regulation that
safeguards people and the environment.
In a fast-moving and complex area the
Biotechnology Strategy is not so much a
blueprint as a compass for guiding direction.
Achieving development with care requires
smart and flexible ways of thinking and
working. To develop the biotechnology
sector we need to foster our science and
research base, build on our strengths and
facilitate links that will promote investment
and commercial growth. We need to apply
biotechnology to add value across a wide
range of New Zealand industries. We need
to pursue ways it can be applied to
contribute to biosecurity, to protect our
environment and our unique biodiversity.
The strategy sets out a vision, goals and
guiding policy principles for the
development and use of biotechnology in
New Zealand. Each goal and its associated
objectives are supported by a set of key
actions. These include actions already
underway, and new initiatives set out in the
2003 Budget. In many cases, objectives and
actions contribute to more than one goal. 
Many of the actions pick up themes
highlighted in the Biotechnology Sector
Taskforce recommendations. Other taskforce
recommendations will be considered in the
context of the GIF processes.
At the core of the strategy is a commitment
to ongoing dialogue between the
community, the sector and the Government,
so New Zealand can achieve a growing
sector that the public trusts. Constructive
community engagement and effective
regulation are goals that underpin
biotechnology growth and development.
Achieving community involvement and
confidence in regulation should not be
regarded as a brake on biotechnology. 
They are a crucial part of the road ahead if
biotechnology is to advance in a 
sustainable way.
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Vibrant and responsible biotechnology sector
Growth
 Education, research, and 
business skills
 Basic research
 Capital investment
 Intellectual Property
management
 Global connections
Effective regulation
 Safeguards health, 
environment and social
values
 Optimises opportunities
 Efficient and transparent
Community understanding
and connection
 Futurewatch
 Information
 Ethics
 Participation
Enhanced wealth, health and environment of New Zealand
Community Engagement
Build understanding about biotechnology and
constructive engagement between people in the
community and the biotechnology sector.
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Biotechnology is a rapidly advancing
technology throughout the world. Like
information and communication
technologies, biotechnology is now providing
powerful tools that will become part of our
everyday lives. With their power comes the
potential to do much good, but also
responsibility for their safe and ethical use.
Biotechnology research and development
needs to be considered in a broad
community context. It must go hand in hand
with an informed, inclusive approach to
decision making about its uses, and take into
account factors beyond those of individual
choice. Consumers and other groups in the
community must therefore have information
and opportunities to be involved.
People will have different needs for
information. Some will want to know why a
particular technique is useful, others will
want to understand how it works, and
others will want to know how any risks can
be managed through regulatory processes,
so they can be part of the discussion over its
introduction. For many new biotechnologies,
New Zealanders will simply marvel and
become early adopters as they have done for
other technologies. Some biotechnologies,
however, will pose questions of cultural,
ethical or spiritual values for some people.
They will want to understand, discuss and
sometimes challenge or even reject, particular
applications on the basis of their values.
Meeting these needs requires a variety of
information and other processes. Many of
these will be interconnected and iterative.
Information helps informed debate and
discussion but it does not necessarily resolve
ethical and values issues. Broad and diverse
perspectives and knowledge need to be
brought to bear on decision-making
processes and sector development.
Researchers and developers must themselves
work to build understanding and positive
connections with different community
groups. The Government also plays an
important role in providing access to quality
information and opportunities for dialogue
and consideration of cultural, ethical and
spiritual issues. 
Objectives 
1. Improve community access to quality information about
biotechnology developments, as well as information on
regulatory processes for assessing potential benefits and
risks and providing safeguards. 
2. Strengthen ways to foresee new and emerging
biotechnologies (futurewatch) with early identification
of potential opportunities and concerns. 
3. Provide opportunities to consider cultural, ethical and
spiritual issues. 
4. Promote active engagement and dialogue between
researchers and developers and different groups in the
community, to enable New Zealanders to contribute to
biotechnology directions in New Zealand.
G O A L
1. Improving access to quality information
11
Many New Zealanders are keen to
understand new biotechnologies. They want
information that explains the science and
how other countries are using these
technologies. They also want information on
the risks and benefits, and on the checks
and balances that are in place here and
overseas. Other people will want
information on the sector, who is doing
what, New Zealand’s areas of strength,
research directions, trends and market
opportunities.
Information must be easily accessible and
easily understood. It must demonstrate a
range of perspectives and be from sources
that are regarded as independent and
trustworthy. The Internet has increased the
ability of people the world over to find and
collect their own information. Establishing a
portal for New Zealand biotechnology
information with links to relevant websites
could be worthwhile. It will also be
necessary to use varied communication
styles and media channels including print,
TV, video and seminars to ensure material
reaches different audiences.
Key Actions
 Make information available on
different aspects of biotechnology
(science, research, the market sector,
regulation and ethics) through a
range of government and non-
government sources, using a 
variety of media. Sources are numerous
and include government agencies,
research institutes, the Royal Society of
New Zealand (RSNZ), sector bodies such
as BIOTENZ and specialist groups. Recent
initiatives include the BiosphereNZ
website and the Royal Society’s DNA50
website. (See Annex Three for a list of
websites.) Consideration will also be
given to the appropriateness of
establishing a New Zealand biotechnology
portal website. 
 Support school biotechnology
education with resources. The
technology curriculum specifies
biotechnology as one of the areas in
which students will be expected to carry
out activities. The science curriculum
strand “Making Sense of Science and its
Relationship to Technology” can use
exemplars from biotechnology. Support
will be given to produce resources to
meet these curriculum needs, including
addressing ethical issues. Companies will
be encouraged to develop programmes
that involve students in biotechnology
activities, such as Genesis Research and
Development’s Harakeke project (see
page 15).
2. Strengthening futurewatch 
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Futurewatch activities scan, analyse and
disseminate information on emerging
developments to provide early alerts of new
opportunities and issues. Many scanning
activities are already in place, especially
through research institutions, industry and
business organisations and within the health
sector, although this activity will not always
be particularly focused on biotechnology.
There is a need to strengthen futurewatch
capacity to enable better and earlier
identification of emerging biotechnologies
that should be discussed by New Zealanders.
Enhanced biotechnology futurewatch
capability, linked to the work of the
Bioethics Council, will provide a source of
information and analysis that can be linked
to processes that involve New Zealanders in
decision making on new biotechnologies. 
It will also improve the Government’s
capability to respond to new biotechnologies
in the New Zealand context, including
biotechnologies that link with other
technological developments such as
nanotechnology.
Key Actions 
 Implement biotechnology
futurewatch activities, to be funded
through Vote Research, Science and
Technology (RS&T). Futurewatch will
scan for emerging biotechnologies and
develop early assessments of issues and
opportunities. These scans and
assessments will feed into the work of 
the Bioethics Council, policy ministries
and other relevant forums.
3. Providing opportunities to consider cultural, ethical and spiritual issues 
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Toi te Taiao: The Bioethics Council, set up by
the Government in response to a
recommendation of the RCGM, will play a
key role in enhancing New Zealand’s
understanding of the cultural, ethical and
spiritual aspects of biotechnology, and
ensuring that biotechnology development has
regard for the values held by New Zealanders.
Amendments to the Hazardous Substances
and New Organisms Act (HSNO) will also
strengthen provisions for consideration of
cultural, ethical and spiritual matters.
Research on social and cultural aspects of
biotechnology are also important in
fostering understanding of the concerns,
values and behaviours that are part of the
New Zealand context for biotechnology
development and use.
Key Actions
 Implementation of the Bioethics
Council work programme. The
Bioethics Council will provide
independent advice to the Government
on biotechnological issues that have
significant cultural, ethical and spiritual
dimensions. It will also provide
information and be involved in public
dialogue on cultural, ethical and spiritual
aspects of biotechnology. 
 Enact amendments to HSNO that
support the consideration of cultural,
ethical and spiritual matters. The
ministerial call-in powers have been
extended to include these matters. 
As well, amendments to reflect better 
the Treaty of Waitangi include adding
knowledge and experience of the Treaty
and tikanga Maori to the knowledge 
and experience that the Minister for the
Environment considers when appointing
members of the Environmental Risk
Management Authority (ERMA) Board.
 Support research into areas of socio-
economic and ethical aspects of
biotechnology. Over the past two years
there has been a significant increase in
funding for social research aspects of
biotechnology. This includes projects such
as “incorporating tangata whenua values
into scientific decision-making”, “ethical
impacts of genetic technologies” and
research on community dialogue models.
4. Promoting active engagement and dialogue
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For New Zealanders to have trust and
confidence in the development of new
biotechnologies, they need to be involved in
discussion and debate about their
introduction. People have expressed a need
to be able to have a dialogue with those
involved in developing the new
biotechnologies.
The aim of dialogue is to develop
constructive relationships between scientists
and developers in the biotechnology sector
and different groups in the community. By
having the chance to share information and
views, people can gain greater trust and
confidence in science and technological
development. The science and technology
community, in turn, can gain greater trust
and confidence in the public’s ability to
contribute to decisions about science issues.
Trust and confidence are not to be
measured by the automatic acceptance or
rejection of new technologies by society.
Dialogue will seek to make science more
responsive to its social context, as well as
increasing community understanding of the
processes and methods of scientific research
and development, including provisions for
ethics and safety.
Key Actions
 Support and facilitate dialogue
initiatives through instruments such 
as the Science and Technology
Dialogue Fund (in Vote RS&T). This
fund has been set up to pilot new ways
of engaging New Zealanders over
scientific developments. The effectiveness
of these approaches will be evaluated and
reported back to the science community.
 Fund outreach activities. These
activities highlight what is behind key
scientific developments, e.g. through
Science Centres, Royal Society activities
and science outreach organised by
community groups through the Science
and Technology Promotion Fund.
 Support the development of Maori
initiatives to develop effective
communication models and resources
that will foster constructive
interaction with Maori communities
on science and research generally, as
well as specifically on biotechnology.
This involves support for initiatives by
organisations such as Nga Kaihautu
Tikanga Taiao, the Maori Advisory
Committee to ERMA and the network of
Maori members of Institutional Biological
Safety Committees; the Crown Research
Institute (CRI) Maori Managers’ network;
the National Association of Maori
Mathematicians, Scientists and
Technologists; and iwi-based science and
technology groups.
 Toi te Taiao: The Bioethics Council. A
key aim of the Council is to promote and
participate in public dialogue, particularly
on cultural, ethical and spiritual aspects of
biotechnology.
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Case Study
School students learn about biotechnology ‘on the job’
A casual visitor to Genesis Research and Development earlier this month would have been
forgiven for thinking that many of the white-coated scientists they saw looked as though
they should still be in school.
In fact, many of the younger brigade are still at school.  They’re the second group of high
school students to spend a week in the labs at Genesis as the culmination of their
involvement in a programme called Harakeke.
Harakeke’s mission is to develop a partnership between the growing biotechnology industry
in New Zealand and secondary schools to promote science teaching and learning and
business growth.  It’s a wide-ranging programme that involves students practically in many
of the biological, commercial, regulatory and legal aspects of biotechnology.
The project is focused on New Zealand flax, or harakeke, and its potential in the biotech
industry.  It aims to put in place a core teaching programme that combines a natural
biological resource and the power of modern biotechnology.
Every Thursday for seven weeks, 14 Year 12 students from Glendowie College have 
spent an afternoon with Genesis staff learning what it means to work as a scientist in 
New Zealand.
The students have had sessions on regulatory, cultural, legal, containment, business and
practical issues as well as hands-on work in a biotechnology company.
During their week in the lab they have been working alongside Genesis scientists
performing the same tasks as the scientists and learning about the technology and science
that underpin Genesis’ work.  This is no simulation.  The students are working on real
projects and making real scientific discoveries.
Growing the Sector
Grow New Zealand’s biotechnology sector to enhance
economic and community benefits.
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A growing biotechnology sector depends on
deep and sophisticated knowledge, skills and
research; investment and infrastructure that
builds on our strengths and recognises the
long path to commercialisation; and strong
links between research and industry here and
abroad to promote the uptake of
biotechnology in beneficial ways. 
The sector taskforce has set itself 10-year
sector growth targets (e.g. a five-fold 
increase in the number of core biotechnology
companies to over 200 from 40) and
identified issues for attention in order to
achieve these targets. The taskforce sees the
sector as having a strong leadership role,
with the Government as a facilitating
partner. The Government has a key
investment role in ensuring science and
research capability. 
The following set of objectives focuses on
areas where the Government has a role to
play and includes areas highlighted by the
sector taskforce. 
GOAL
Objectives
1. Strengthen capability - in science education, basic
research, enterprise and commercial skills.
2. Build critical mass around areas of strength. 
3. Facilitate investment for commercialising 
New Zealand biotechnology research. 
4. Promote the application of biotechnology to add
value to New Zealand industries.
5. Increase global participation.
6. Ensure biotechnology research to address sustainability,
biosecurity and protection of biodiversity. 
G O L
1. Strengthening capability
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To achieve a vibrant world-class
biotechnology sector in New Zealand, we
must make sure that New Zealand has the
underlying capabilities. We need talented
scientists, innovative ideas, excellent
research and the skills to link people,
research ideas and industry. 
The needs of a dynamic sector like
biotechnology call for high general levels of
science, research and commercial skills, as
well as specific specialist skills.
Key Actions 
The following action areas require ongoing
attention:
 Enhance science and technology
education at all levels 
Lifting general skill levels in science
requires a focus on both participation and
achievement. Since 1999 the New Zealand
school system has introduced a new
technology curriculum that is compulsory
from Years 1 to 10 and includes
biotechnology as an area of focus.
Successfully implementing this curriculum
is the current challenge, with a need for
supporting material, teachers qualified to
teach biotechnology and stronger links
between the science and technology
teachers. The National Certificate of
Educational Achievement now makes it
possible to study biotechnology through
to Year 13, providing a broader pathway
to tertiary study. The Government’s
Tertiary Education Strategy provides a
sound framework for supporting this
objective in the tertiary sector. 
Enhancing skill levels will involve:
 lifting participation in science and
technology, especially at the senior
secondary and tertiary levels;
 lifting Maori and Pacific participation
and achievement in science and
technology;
 professional development and support
for science and technology teachers;
 development of technology curriculum
material related to biotechnology;
 implementing scholarship and
fellowship programmes to support
post-graduate science and
biotechnology research;
 industry bodies and government
agencies working jointly to identify
specific capability and skills gaps 
and work on ways to address 
those needs.
 Recruit and retain scientists and
science entrepreneurs 
 Working with industry on an industry-
initiated programme of active
recruitment and repatriation of science
and entrepreneurial talent. This may
include tapping into the New Zealand
diaspora through programmes such as
“World-class New Zealanders”, and
greater use of scholarships and
fellowships. 
 Foster and draw on Maori biological
knowledge and innovative capacity
Consultation has shown a clear need to
foster and use Maori strengths in the
areas of natural resources, their beneficial
uses and ecological management. Work
programmes in this area include:
 MoRST work on fostering the creative
potential of Maori as innovators,
researchers and thinkers. This will
involve developing RS&T policies
targeted towards a stronger emphasis
on Maori creative potential while
maintaining an appreciation of social
justice and Treaty issues;
 the work of Maori research units at
universities and wananga, including
the work of Nga Pae o te
Maramatanga, The National Institute
for Maori Development and
Advancement;
 Ministry of Economic Development
(MED) work on the protection of
traditional knowledge, innovations and
creativity, in relation to intellectual
property and bioprospecting policy.
 Invest in excellent fundamental
research
Consultation also reinforced the need to
maintain a strong base of fundamental
research as the foundation for innovation.
Excellence in fundamental research has
been a strength and hallmark of 
New Zealand biotechnology and we must
ensure this continues to be the case. The
Government is a key player here and has
in recent years steadily lifted the level of
investment in biotechnology research.
Actions include:
 implementing the Centres of Research
Excellence (CoREs). Over the past two
years the Government has initiated
significant new operational and capital
funding to build critical mass and
extend the research programmes in
selected areas of research excellence.
Four of the seven CoREs are strongly
grounded in biotechnology. (See
Annex Three for website link to RSNZ
and Centres of Research Excellence.)
 implementing Performance-Based
Research Funding to strengthen
excellence in tertiary research;
 building and enhancing the capability
of CRIs;
 funding increases in the Marsden
Fund, the New Economy Research
Fund (NERF) and the Health Research
Council (HRC). 
 Develop commercial skills and
experience
New Zealand needs to have ‘commercially
savvy’ scientists and ‘scientifically savvy’
industry managers. This calls for:
 implementing cross-disciplinary links at
tertiary institutions;
 greater exposure to best international
practices, e.g. Industry NZ working
with industry to promote best practice,
especially in intellectual property
management.
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2. Building critical mass around areas of strength
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New Zealand biotechnology will thrive if 
it can draw on its areas of existing and
emerging strengths and link these with
realistic market opportunities. The sector
taskforce has identified key areas of strength
and depth that will give us particular
opportunities. These include large animal
and plant-based biotechnologies;
bioprocessing technologies and
biomanufacturing; innovative foods and
nutraceuticals; as well as small but vibrant
biomedical groupings in niche areas,
especially asthma, diabetes, bone health,
neuroscience and cardiovascular disease. 
Promoting clustering and collaboration
around areas of strength will be important
and the taskforce has identified this as a key
area of sector leadership. The Government
can support building critical mass,
particularly through research funding
mechanisms that encourage collaboration
and focus on excellence in areas of strength.
Key Actions 
 Strengthen strategic approaches to
biotechnology research funding. As
the major research funder, the
Foundation for Research, Science and
Technology (FRST), working with the
sector, is increasingly developing strategic
approaches to research funding that will
build on strengths and enhance critical
mass and collaborative links. This
approach also must be co-ordinated with
biotechnology-related research funding
through the Marsden Fund, CoREs and
the HRC. International peer review will be
an integral part of benchmarking
excellence and strategic focus.
 Co-ordinate planning for major
infrastructure investment in capital
equipment and platform
technologies. This also requires close 
co-ordination between research
institutions and government funding
agencies (FRST, the HRC, the Tertiary
Education Commission (TEC), RSNZ, 
and Industry NZ). Examples of such
infrastructure include next-generation
Internet links and bioinformatics
databases.
 Support clustering and developing
effective collaboration and alliances.
This support is currently provided by
Industry NZ, through its Biotechnology
Directorate. This will be further enhanced
through the newly merging agency, 
New Zealand Trade and Enterprise (NZTE)
combining industry, investment and 
trade support. 
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3. Facilitating investment in commercial development
Attracting capital into commercial
development of biotechnology is a challenge
worldwide. Investment in biotechnology,
throughout all its phases from research to
manufacture and marketing, is at the higher
end of the risk spectrum. The pathway,
particularly for bio-pharmaceuticals, is
longer, more costly and has more chance 
of failure than for most other technologies. 
(For instance, US$800 million is a benchmark
figure to take a new drug from discovery 
to market.) 
For New Zealand, our high number of small
start-up companies, relatively poorly
developed commercial skills, small domestic
investor market and distance from global
biotechnology and investors heighten this
growth challenge. Constraints concerning
access to capital can be acute at early stages
of development, as businesses seek to
develop ideas into new commercial products
and processes, and ‘prove’ the concepts. 
Key Actions
 Provide funding to increase the rate
of commercialisation, particularly at
the early stages of commercial
development, including: 
 supporting the public funding
mechanisms already available to 
foster commercialisation, including
Technology for Business Grants,
Grants for Private Sector Research 
and Development and Industry NZ
funding grants; and the New Zealand
Venture Investment Fund; 
 implementing a new pre-seed
accelerator fund; 
 providing more flexibility in FRST
funding of experimental development
so projects can be funded up to the
pre-seed stage of commercialisation. 
 The Government will also consider 
the Biotechnology Taskforce
recommendation for a private-public
funding mechanism, specifically
targeted to biotechnology
development, with flexibility to span
all stages of commercialisation.
4. Applying biotechnology in New Zealand industries 
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The application of modern biotechnology
research can add value to the products and
processes of many New Zealand industries
including agriculture, forestry, marine,
environmental and pest management, 
and human and animal healthcare. To gain
these benefits and ensure international
competitiveness it is important to promote
speedy and widespread diffusion of
biotechnology into the broader industrial
community, while maintaining responsible
and sustainable use.
Industry initiative and entrepreneurship are
essential. The Government can promote
research-industry linkages and facilitate
market information including technological
and commercial trends and opportunities.
Key Actions
 Stimulate market-led research,
especially through the development 
of a best practice programme jointly
developed by industry, CRIs and tertiary
research providers for achieving 
effective connections between industry
and science. 
 Encourage early collaboration
between research providers and
businesses, especially through funding
instruments that provide incentives to link.
Examples include FRST’s Research for
Industry funding, Research Consortia and
TechNZ funding.
 Promote the enabling aspects of
biotechnology to a wide range of
industry sectors, especially building on 
the synergies between the biotechnology
and the primary sectors. Government
agencies, such as the Ministry of
Agriculture and Forestry (MAF) and NZTE
can facilitate through communicating
biotechnology market information and
demonstration projects that promote 
the integration of biotechnology 
into industries.
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Case Studies
Selling naturally ‘good’ bugs
Preventing tooth decay by using the human body’s naturally occurring ‘good’
bacteria is being investigated by New Zealand company BLIS Technologies.
Clinical trials, in association with the Otago University Dental School, began in
February 2003 with the aim of developing a bacterium-containing product that,
when used with brushing, will combat plaque and thus prevent tooth decay.
The company has also lodged a patent for a bacterium to combat ear infections.
The bacterium, which appears naturally in the nasal passages of healthy children,
has shown promise in preventing ear infections and sinusitis.
Early lab trials show the bacterium inhibits a variety of bugs that lead to ear infections. 
Used after a course of antibiotics, it could help replenish the body’s natural defences. 
Pilot trials with people suffering chronic ear infections are planned.
BLIS Technologies was formed in June 2000 to build on Otago University work and pursue 
the commercialisation of “BLIS" - Bacteriocin-Like Inhibitory Substances.
It already has two products on the market - BLIS K12 Throat Guard, containing beneficial 
bacteria, and BLIS Bio Restore, which restores naturally occurring good intestinal and oral 
bacteria following antibiotic use.
When antibiotics are taken, the good bacteria necessary for everyday well-being are killed along
with undesirable bugs, upsetting the body’s natural balance and making people prone to side effects.
Research to prevent asthma
The human body’s immune response to tuberculosis micro-organisms could lead to a vaccine to
prevent asthma.
Asthma is caused by the inflammation of over-sensitive breathing tubes in the lungs.  Research has
revealed that an over-active immune system is the underlying cause of the smooth muscle, mucus
and nerve changes seen in the lungs of many asthmatics.  Evidence has also been found that
exposure to some types of infection, including Tb, may actually decrease the prevalence or severity
of asthma.
Research by scientists at the Wellington-based Malaghan Institute, working in collaboration with
the University of Otago and AgResearch, includes trying to find ways to switch off or block the
body’s ‘Th2’ cell immune response in order to alleviate asthma symptoms. Th2 
cells, which produce a specific set of hormones that can damage lung tissue,
have been identified as a principal culprit in asthma.
Scientists have found that key molecules produced by the Tb vaccine can
stimulate a ‘protective’ infection, and by doing this, block the development 
of asthma symptoms.
A preliminary clinical trial revealed potential for unwanted reactions, and work
is now concentrated on extracting the active ingredients.  Other infectious agents
are also being screened for their ability to suppress the onset of asthma.
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Nutraceuticals from the sea
The National Institute of Water and Atmospheric Research (NIWA) and Ngai Tahu
Seafood are working together to develop ‘nutraceuticals’, in particular
biologically active compounds highly sought after in the cosmetics industry for
natural skin care products.
New Zealand has an extremely diverse marine environment that presents huge
bioprospecting potential.  The NIWA-Ngai Tahu partnership brings together
expertise in fisheries and aquaculture, bioactive research and nutraceutical
development. The two organisations are aiming to source, screen and extract compounds from the
by-products and by-catch of New Zealand’s fisheries and aquaculture species.
Ngai Tahu Seafood is taking the lead role in the commercialisation stage, having already identified
a range of skin care companies interested in the research. It has identified high-value seafood-based
nutraceuticals as an area with commercial potential.
NIWA will screen hundreds of compounds to identify potential activity. The type of compounds
sought for skin care products are antioxidants, used in anti-aging creams and moisturisers, and
vasodilators, which have a relaxant effect on arterial and smooth muscle.
When promising candidates are found the compounds will be purified and the chemical structure
determined through further assays and techniques such as nuclear magnet resonance (NMR). It will
also be essential to check whether the compounds are unique so the organisations can protect their
intellectual property. 
Leveraging our biotechnology strengths
Dunedin-based biotech company Ovita is using sheep genome research to help farmers improve 
the quality and productivity of their stock.
The research is not about changing genes, but understanding them and knowing which ones can be
passed on conventionally from one generation to the next or mimicked through new vaccines.
Ovita, a New Zealand Wool Board, Meat New Zealand and AgResearch consortium, has identified 
a number of genes that regulate fertility, along with proteins that regulate ovulation rate. A key
discovery is the ‘Inverdale’ gene - in female sheep one copy causes twins, two copies make the
sheep sterile.
Some markers associated with increased reproduction are ready to be commercialised. Ovita expects
that in one to two years it will also have developed additional marker tests to help
farmers identify sheep with the genetic capability for premium meat production,
as well as a test for lice. In two to three years it expects to have a test to detect
Johne’s disease early, followed by an improved vaccine and in 10 years a new
vaccine, and in three to five years to have developed marker tests for desirable
body composition, lamb survival and parasite and facial eczema resistance.
As well as offering potentially tremendous benefits to farming, the research will
be commercialised in non-agricultural areas such as human therapeutics and
veterinary products.
Case Studies
5. Increasing global participation
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Industry and the Government together can
foster international connections that benefit
New Zealand. We have much to gain
through international links that inform other
countries about New Zealand’s world-class
expertise in biotechnology. We will also gain
from collaborating with other countries in
ways that offer New Zealand better access
to specialist expertise, high-cost research
facilities, new technology and investment. 
Key Actions
 Promote New Zealand biotechnology
with integrated profiling and national
branding. A start has been made with
the BiosphereNZ website set up by
Industry NZ and the sector, joint industry-
government participation in major
international conferences, such as
Bio2002 and Bio2003 and showcasing
missions in Australia. The Government is
committed to further joint international
showcasing including hosting high-profile
events in New Zealand, such as the APEC
innovation showcase. 
 Build focused country and regional
links. Focused country partnerships and
regional links can enable greater traction
through joint development and
showcasing. Industry and government 
will need to work together to achieve
these partnerships in ways that support 
New Zealand’s major trading interests
and provide mutual benefit for all
partners. Building stronger biotechnology
links with Australia is a priority and
discussions and exchanges are already
underway. The United States of America
and East Asian economies, principally
Korea and Singapore, are also important
partners for scientist-to-scientist links and
for the commercial development of
biotechnology. 
 Represent New Zealand’s interests in
and contribute to the multilateral
policy arena for the debate and
development of international
biotechnology protocols. Themes of
interest for international harmonisation
include privacy and security, protection of
information, food safety, biological
diversity, regulation, standards and ethics.
Relevant international fora include Asia
Pacific Economic Co-operation (APEC),
Organisation for Economic Co-operation
and Development (OECD), United Nations
Educational, Scientific and Cultural
Organisation (UNESCO) (bioethics), World
Health Organisation (WHO), World Trade
Organisation (WTO) and UN Food and
Agricultural Organisation (FAO), the
Codex Alimentarius Commission, and the
World Intellectual Property Organisation. 
6. Biotechnology research to address sustainability and biosecurity, and protect biodiversity 
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The capacity of biotechnology to contribute
to environmental sustainability, biosecurity
and protection of biodiversity was
highlighted during consultation. Examples
include reduction of methane emissions
from farm animals; control options for major
pests, such as possums; cleaner industrial
processes; and taxonomic methods to
understand and describe our unique flora
and fauna. The Government is committed to
a proactive approach to funding research
and development in these areas.
Key Actions
 Fund Centres of Research Excellence.
Two of the CoREs; the Allan Wilson
Centre for Molecular Ecology and
Evolution and the National Centre for
Advanced Bio-Protection Technologies are
world-class research centres addressing
these matters. They have significant
government funding to enhance their
capacity and extend their research
programmes.
 Fund specific sustainability and
bioprotection research projects –
through the FRST ‘Sustainablity’
research category. 
 Fund biotechnology impacts research
– through the FRST ‘Sustainable
Biotechnology’ portfolio.
 FRST, in conjunction with the Ministry
for the Environment (MfE), the
Department of Conservation (DoC),
and MAF is to develop a research
strategy for environmental
biotechnology.
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Case Studies
Bio-cleanup of contaminated sites
Scientists at the CRI HortResearch have found a native white-rot fungus that may
be able to clean up toxic sawmilling sites.
Until 1988, pentachlorophenol or PCP was used in New Zealand sawmills as a
timber preservative. Its use was stopped after PCP was found to be toxic and
persistent in the environment, but there are now around 800 former or existing
sawmilling sites in New Zealand that need cleaning up.
HortResearch has identified a native white-rot fungus that can significantly degrade PCP into 
non-toxic compounds, even when the PCP is at moderate concentrations.
The scientists are now looking to refine further the use of this fungus and use it as a commercial
product for cleaning up contaminated sites. There are also good prospects for taking this 
technology overseas.
The research is part of HortResearch’s ‘bioremediation’ work, a branch of biotechnology that uses
biological processes to overcome environmental problems. This often involves treating waste or
pollutants using micro-organisms, such as bacteria and fungi, which can break down
environmentally unfriendly substances.
The potential for trees, particularly poplars and willows, to be used to suck up heavy metals from
contaminated environments is also being investigated. Some species are capable of extracting large
amounts of cadmium, boron and other metals or metalloids.
Gene historians learn from the past
A dramatic acceleration in our understanding of the processes underpinning the ecology and
evolution of living systems is expected to result from research by the Palmerston North-based Allan
Wilson Centre for Molecular Ecology and Evolution.
The Centre, working with Otago, Canterbury, Victoria, Massey and Auckland Universities, is 
using new tools involving DNA technology and mathematics to study the ecology and evolution of
New Zealand plants, animals and micro-organisms. 
Recent research, using new techniques such as sequencing of genomes and the study of ancient
DNA, has revolutionised our understanding of New Zealand’s biodiversity. The concept that 
New Zealand is a ‘Moa’s Ark’ of relic species, undergoing ancient and slow changes over long
periods of time, has been overturned by the information obtained using these techniques.
The research can also provide insights into how New Zealand plants and animals will respond to
future environmental changes, such as climate change, based on how they
reacted in the past.
The Centre’s research programme includes projects on rates and modes of
evolution, biodiversity, human settlement of New Zealand, and new ecological
and evolutionary models.
Scientists will be aided by Massey University’s newly developed supercomputer 
‘The Helix’ - the fastest computer in New Zealand – using applications designed to
analyse large amounts of data such as DNA information.
Regulation that Provides Robust Safeguards and Allows Innovation
Manage the development and introduction of new
biotechnologies with a regulatory system that
provides robust safeguards and allows innovation. 
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The design and operation of regulations
must achieve robust safeguards for people
and the environment while minimising cost
and complexity. The regulatory framework is
where innovation and opportunity meet
society’s safety and ethical concerns. The
challenge is to ensure an appropriate
balance.
The diagram in Annex One summarises the
main components of the regulatory system
governing the introduction of new
bioproducts and biotechnologies. This
framework shows the different approval
processes and institutions for food, animal,
crop and medicinal developments.
Intellectual property law and bioprospecting
regulations are important elements of the
regulatory framework surrounding
biotechnology. Getting intellectual property
law and practice right is vital for supporting
New Zealand innovation.
Transparency, predictability and best
regulatory practice are essential. The ability
to maintain an overview of the system as a
whole will also be important in assessing
how well it is achieving a balance between
assurance and innovation.
Objectives
1. Ensure regulation effectively assesses and manages risks
from the introduction of new biotechnologies.
2. Complete and implement the reviews of the Patents 
Act, the Plant Variety Rights Act and bioprospecting
regulation. 
3. Promote greater transparency and best regulatory
practice in the sector. 
4. Maintain an overview of the biotechnology-related
regulatory system to ensure effectiveness and
efficiency, and provide for assessments of how well it is
achieving a balance between assurance and innovation. 
G O A L
1. Regulation to assess and manage risks from new biotechnologies effectively
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Together, the regimes outlined in Annex
One provide a comprehensive and stringent
system to achieve safety and environmental
protection. The system is participatory, and
provides structured opportunities for public
consultation and submissions.
New Zealand’s case-by-case assessment
approach is similar to that of a number of
jurisdictions, including Canada, Australia,
Japan and the European Union, although
specific regulatory requirements may differ.
A case-by-case assessment process is also
consistent with approaches agreed
internationally through the Cartagena
Protocol on Biosafety.
Concerns about some newly emerging
biotechnologies will occasionally prompt
particular regulatory scrutiny. Genetically
modified organisms (GMOs) have been one
such case. Following extensive consultation
and deliberation, the RCGM found that the
basic regulatory system was sound in
relation to GMOs, and that key institutions
were sound in carrying out their functions.
The Royal Commission proposed
amendments requiring specific consideration
and controls for the field testing and release
of new organisms, including GMOs. The
Government, following policy work and
consultation on the discussion document
“Improving the Operation of HSNO for New
Organisms”, has announced a set of
amendments to HSNO. 
Further areas for current regulatory attention
are the therapeutic use of organs and tissues
and assisted human reproduction
technologies. While human reproductive
cloning is now a restricted procedure
through recent legislative amendments to
the Medicines Act, work is underway to
legislate for managing therapeutic uses of
human organs and tissues, and to
implement a regulatory framework for
assisted human reproductive technology.
Key Actions
 Enact and implement the changes to
HSNO, including:
 streamlining the approval process for
laboratory research involving the
development or import of low-risk
GMOs;
 addressing some regulatory gaps
relating to new technologies and
human cells;
 streamlining the approval process for
medicines and veterinary medicines
that are or contain new organisms;
 fast-tracking approvals of medicines
and veterinary medicines for use in
emergencies;
 strengthening incentives to comply
with HSNO by establishing liability for
harm caused by non-complying
activities and a civil penalty regime for
breaches of HSNO or approvals
granted under the Act;
 extending the ministerial call-in powers
to include cultural, spiritual and ethical
matters; 
 including provision for ERMA to
impose conditions on the release of
new organisms – a new conditional
release category;
 extending the existing regulation-
making powers relating to the impacts
of hazardous substances, to also cover
conditionally released new organisms; 
 establishing MAF as the primary
enforcement agency for conditional
release, new organisms in containment
and unauthorised releases of new
organisms;
 clarifying ERMA’s responsibilities
regarding the protection of releasing
confidential information that is
included with an application to ERMA;
 removing the requirement for
contained fermentations of more than
10 litres of new organisms to be
considered as field tests and instead to
be considered as a development;
 measures to more appropriately reflect
the Treaty of Waitangi relationship in
the administration of the Act.
 Enact the Human Assisted Reproduction
Technology Bill - to regulate the use of
human reproductive technology. The Bill
establishes a three-tier framework for
ethical decision making consisting of:
 prohibitions on fundamentally
unacceptable practices, such as
reproductive cloning;
 a Ministerial Advisory Committee
which will be established to provide
advice and develop guidelines for
those operating in this area; 
 mandatory ethical approval for non-
established procedures, such as newly
developed techniques to aid fertility,
and for all research.
 Update the Human Tissue Act in light of
new social and technological
developments in relation to the use of
human cells and tissues. 
 Implement biotechnology futurewatch
activity to help early identification of and
work on potential regulatory issues from
emerging biotechnologies.
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2. Completing and implementing reviews of the Patents Act, the Plant Variety Rights 
Act and bioprospecting regulation 
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Intellectual property protection and
management are significant elements in
improving the pathway from innovation to
making new products and services
commercially available. This in turn will
encourage the generation of economic
value. As with other regulatory regimes
there is a need for balance; to set the need
for individual incentives and a fair return for
innovation and development investment
alongside other collective objectives, such as
early, low-cost public access to generic
pharmaceuticals or genetic testing
techniques. 
The Government is committed to updating
the Patents Act and Plant Variety Rights Act
to take new social and technological
developments into account. Submissions on
a discussion document were extended to
consider the issue of patent extensions. 
The Government will pursue introducing
amendments arising from these reviews
during the 2003 parliamentary term.
Bioprospecting is the examination of
biological resources for features that may be
of value for commercial development. While
bioprospecting in New Zealand is in its
infancy it has the potential to create a wide
range of benefits for New Zealand. The
Government is examining policy options for
formulating a framework to manage access
to biological resources for bioprospecting.
This framework will include a policy for
benefit sharing, including recognising Maori
interests in relation to biological resources.
Key Actions
 Pursue introducing amendments
arising from the reviews of the Patent
and Plant Variety Rights Acts, during
the 2003 parliamentary term.
 Complete, by December 2003, the
review of New Zealand’s regulation of
bioprospecting activities to establish
an overarching policy framework.
3. Promoting greater transparency and best regulatory practice
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To support the regulatory design there is a
need to promote greater transparency and
best operational practice in the sector for
safety and ethical approvals, including best
ways to work in partnership with Maori
authorities and take account of the Treaty of
Waitangi. Firms and research organisations
also need to develop sound intellectual
property management practices,
understanding what, when and how to
protect new ideas. Best regulatory practice
can contribute considerably to minimising
costs and complexity. 
Sector bodies such as Biotenz, and
government agencies including ERMA,
Industry NZ and the HRC, can jointly play a key
role in fostering and spreading best practice.
Key Actions
 Hold best regulatory practice
workshops – led by sector groups and
supported by government agencies.
 Provide targeted industry advice on
biotechnology-related legislation – to
be led by relevant government agencies
working jointly with the sector.
 Develop an Intellectual Property
Management Manual specifically for
biotechnology – to be led by NZTE
working jointly with the sector. 
4. Oversight of the regulatory system to ensure effectiveness and efficiency
32
The diagram in Annex One summarises the
different approval processes and institutions
for food, animal, crop and medicinal
bioproducts and biotechnologies. While, as
the sector taskforce has noted, it is in our
trading interests to keep a gold standard for
safety, we must do so in a way that supports
innovation and does not load the system
with unnecessary complexity and costs. 
A number of agencies, such as MfE, the
Ministry of Health (MoH), the New Zealand
Food Safety Authority (NZFSA) and MAF
have regulatory oversight of specific
elements of the system. There is, however, a
need to assign responsibility for oversight of
the system as a whole, to consider the
multiple and dynamic links, and particularly
the interactions between regulation and
innovation. This is not easy, but other
countries, notably Canada, are starting to do
it, especially with regulations related to key
platform technologies.
In line with MoRST’s whole-of-government
co-ordination role for biotechnology, it is
appropriate to assign overview to MoRST, in
liaison with other key agencies and industry.
As part of this overview activity, the
Government has made provision for the
conduct of periodic independently
contracted system audits to assess whether
the regulatory regime and its operation are
achieving an appropriate balance between
assurance and innovation. 
Key Actions
 Assign MoRST an overview role in
relation to biotechnology-related
regulation, in liaison with key
agencies and sector bodies. 
 Conduct periodic independently
contracted system audits to assess
whether the regulatory regime and 
its operation are achieving an
appropriate balance between
assurance and innovation. 
Keeping the Strategy Fresh - Leadership and Co-ordination
The dynamic, multi-layered and long-term
nature of biotechnology development
requires a commitment to support the
strategy with co-ordinated information and
action, regular communication and
monitoring. Clear government leadership
will be central to the ongoing balancing of
development and assurance policy
considerations.
It is crucial that the ‘development with care’
perspective informs the work of the wide
range of government ministries and Crown
and government-funded agencies with
responsibilities and interests in
biotechnology in New Zealand. Among the
key agencies are those which:
 support the science, research and skill
base at the core of biotechnology,
including MoRST; FRST; the HRC; RSNZ;
the Ministry of Education and increasingly
the TEC;
 facilitate industry development and 
trade and investment activity around
biotechnology, including the
Biotechnology Directorate in the 
newly integrated Trade and Enterprise
agency and the Ministry of Foreign 
Affairs and Trade;
 oversee policy regulation and ethical
standards relevant to biotechnology,
including MfE, which is also responsible
for supporting Toi te Taiao: The Bioethics
Council; MoH, MAF, MoRST, and DOC; 
 increase public awareness and provide
information about biotechnology (MoRST,
MfE, RSNZ and NZTE);
 oversee policy of the key linked ‘growth
and innovation’ and ‘sustainable
development’ frameworks, including
MED, the Department of Prime Minister
and Cabinet and the Treasury.
There are also other Crown agencies and
advisory bodies with biotechnology-related
work programmes and responsibilities. 
These include regulatory bodies such as
ERMA and Food Standards Australia 
New Zealand (FSANZ), ethical bodies such 
as the Health Research Council Ethics
Committee (HRCEC), CRIs and tertiary
research providers.
No one agency can hold all responsibilities,
so co-ordination and joint responsibility for
implementing a common framework
through policy and operational activities 
are essential.
Government leadership will be provided
through key Ministers who will oversee and
support a balanced and integrated approach
to biotechnology in New Zealand. The
Ministers will be convened by the Minister 
of Research, Science and Technology and
will include the Minister of Economic
Development, the Minister for the
Environment, the Minister of Health, the
Minister of Agriculture and Forestry and the
Minister of Finance. 
The Biotechnology Sector Taskforce has
confirmed the need to strengthen and
consolidate industry association efforts in
one body. It is also planned that the sector
taskforce reconvene periodically to monitor
and review progress against the taskforce
growth targets.
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Meeting Expectations – What Will Change 
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We will know this strategy has worked if there is:
 growing public awareness of new biotechnology developments;
 public confidence in the way the sector carries out its work; 
 significant movement towards sector growth targets;
 greater depth of expertise across the biotechnology sector which ensures opportunities are
being seized to realise the benefits of New Zealand’s world-class research;
 greater depth and breadth in biotechnology global linkages;
 public confidence that the regulatory system provides the necessary safeguards;
 confidence among researchers that the regulatory system is able to accommodate innovation;
 stronger co-ordination between key players in the biotechnology sector and relevant
government agencies. 
Annex One
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The Current Regulatory Framework for Approving New Biotechnology Products
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Abbreviations
ACVM Agricultural Compounds and Veterinary Medicines Act 1997
APEC Asia Pacific Economic Co-operation
DG Director General 
CRI Crown Research Institute 
DoC Department of Conservation
ERMA Environmental Risk Management Authority 
FAO UN Food and Agricultural Organisation
FSANZ Food Standards Australia New Zealand
FRST Foundation for Research, Science and Technology 
GIF Growth and Innovation Framework
GMO Genetically modified organism 
GTAC Gene Technology Advisory Committee
HRC Health Research Council
HSNO Hazardous Substances and New Organisms Act 1996
HRCEC Health Research Council Ethics Committee
IBAC Independent Biotechnology Advisory Council (ceased existence in July 2002)
IBSC Institutional Biological Safety Committee 
MAAC Medicines Assessment Advisory Committee 
MED Ministry of Economic Development
MfE Ministry for the Environment
MoRST Ministry of Research, Science and Technology 
NECAHR National Ethics Committee on Assisted Human Reproduction
NERF New Economy Research Fund
NZTE New Zealand Trade and Enterprise (new Government agency, operative from 
July 2003, formed from the integration of Industry New Zealand, Investment 
New Zealand and Trade New Zealand)
OECD Organisation for Economic Co-operation and Development
RCGM Royal Commission on Genetic Modification
RSNZ Royal Society of New Zealand
SCOTT Standing Committee on Therapeutic Trials 
UNESCO United Nations Educational, Scientific and Cultural Organisation
VIF New Zealand Venture Investment Fund 
WHO World Health Organisation
WTO World Trade Organisation
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Angel investment: Early, pre-seed funding
for new start-up businesses; this investment
is usually in the form of equity and involves
‘hands on’ business advice.
Biotechnology: Any technological
application that uses biological systems,
living organisms or derivatives thereof
(whether genetically modified or not) to
make or modify products or processes for
general use. 
Biodiversity, biological diversity: The
existence of a wide range of different 
types of species (e.g. plant and animal) at 
a given time. 
Bioinformatics: A computer-based
discipline that organises biological data from
DNA and protein sequencing and provides a
technique for computer imaging and
modelling of biological systems.
Bioprospecting: Examination of biological
resources (e.g. plants, animals, micro-
organisms) for features that may be of value
for commercial development.
Bioremediation: The use of biological
systems to clean up pollution and other
environmental contaminants.
Chromosome: Components in a cell that
contain genetic information. Each
chromosome contains numerous genes.
Clone: An identical copy of something. 
The term may be applied to a piece of DNA,
a cell or individual plants or animals such as
identical twins.
Codex Alimentarius Commission:
This Commission was created in 1963 by 
the Food and Agricultural Organisation
(FAO) and the World Health Organisation
(WHO) to develop world food standards,
guidelines and related texts such as codes of
practice under the joint FAO/WHO Food
Standards Programme.
DNA: Deoxyribonucleic acid, the chemical at
the centre of the cells of all living things,
which controls the structure and function of
each cell and carries genetic information
during reproduction. 
Gene: A sequence of DNA on a
chromosome that contains an instruction for
a cellular function that is inherited. 
Genetic modification: Altering the genetic
material of cells or organisms to make them
capable of making new substances or
performing new functions. Also referred to
as genetic manipulation and genetic
engineering. 
Gene therapy: The process of introducing
new genes into cells to correct a genetic
disease. 
Horizontal gene transfer (HGT): Refers to
the movement of a gene from one species
to another. HGT is a naturally occurring
process, especially among bacteria. HGT
between plants and bacteria may occur, but
only extremely rarely. It is distinct from the
normal process of vertical gene transfer
(from parent to offspring) which occurs in
reproduction.
Intellectual property: The area of law
involving patents, copyrights, trademarks,
trade secrets and plant variety protection.
Matauranga Maori: This is a Maori world
view that embraces science and the
development of science from within a
cultural framework.
Nanotechnology: Sometimes called
“molecular manufacturing” or “micro-
robotics” . It involves the development and
use of devices that have a small size (of only
a few nanometers). 
Nutraceutical, nutriceutical: A food
product that includes improved nutritional
characteristics and/or pharmaceutical
properties.
Patent: The exclusive right to make use of
an invention for a fixed time. 
Plant variety rights: The exclusive right to
produce a new plant variety for sale and to
sell propagating material. 
Stem cells: Cells that have the ability to
continuously divide and develop into various
types of tissues. Can be sourced from early
embryos, foetuses, umbilical cord blood and
adult tissues (e.g. bone marrow). 
Therapeutic cloning: A technique whereby
people can provide their own somatic (adult
cell) nuclei to replace nuclei in their own or
donated eggs, so that individual embryonic
stem cells can be developed. The embryonic
stem cells can then be used to replace tissue
that has been damaged by injury or disease.
This technique is being investigated for the
treatment of Parkinson’s and Alzheimer’s
diseases. 
Transgenic: An organism that has been
genetically engineered to contain genes
from another species.
Wai 262: Claim to the Waitangi Tribunal
from six iwi and one whanau, which claim
exclusive and comprehensive rights to
indigenous flora, fauna and other ‘taonga’
such as traditional knowledge.
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Annex Three – Biotechnology-Related Web Links
NEW ZEALAND LINKS
Biosphere New Zealand – www.biospherenz.com
An industry initiative to showcase business and investment information on 
New Zealand's rapidly growing biotechnology sector. 
BIOTENZ – www.biotenz.org.nz
BIOTENZ is a group of leading New Zealand providers of biotechnology, natural, pharmaceutical
and biological products and services. BIOTENZ is supported by Trade New Zealand.
Crown Research Institutes
AgResearch – www.agresearch.cri.nz
Crop and Food – www.crop.cri.nz
Forest Research Institute – www.forestresearch.co.nz
Geological and Nuclear Sciences – www.gns.cri.nz
HortResearch – www.hortresearch.co.nz
Industrial Research – www.irl.cri.nz
Institute of Environmental Science and Research – www.esr.cri.nz
Landcare Research – www.landcareresearch.co.nz
National Institute of Water and Atmospheric Research – www.niwa.cri.nz
Environmental Risk Management Authority – www.ermanz.govt.nz
ERMA New Zealand controls the introduction of new plants and animals, including GMOs and
new and existing hazardous substances to New Zealand.
The Independent Biotechnology Advisory Council – www.ibac.org.nz
Although IBAC ceased to operate in August 2001, its website remains an excellent source of
research and reports.
Industry New Zealand – www.industrynz.govt.nz 
This website showcases New Zealand’s brightest businesses, entrepreneurs and opportunities.
Ministry of Agriculture and Forestry – www.maf.govt.nz
MAF is about agriculture, horticulture and forestry, safe food, a protected environment, the
wise use of the land, the creation of clean, green product and the economic success of those
who produce it.
Ministry for the Environment – www.mfe.govt.nz
MfE works with others to identify New Zealand’s environmental problems and get action on
solutions. Its focus is on the effects people’s everyday activities have on the environment, so its
work programmes cover both the natural world and the places where people live and work.
Ministry of Health – www.moh.govt.nz
MoH is the Government's primary advisor on health policy and disability support services.
Ministry of Research, Science & Technology – www.morst.govt.nz
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New Zealand Biotechnology Association – www.biotech.org.nz
The New Zealand Biotechnology Association website provides a gateway to a directory of
New Zealand biotechnology companies, university departments and research institutes.
Also included are reports on annual conferences and other international biotech conferences
planned for the future.
New Zealand Government Genetic Modification Website – www.gm.govt.nz
This site aims to give New Zealand citizens access to a broad range of information relating to
genetic modification, how it is used and how it is controlled.
Royal Society of New Zealand – www.rsnz.govt.nz 
The Royal Society is an independent academy of sciences and an association for the
advancement and promotion of science and technology. The Royal Society administers a
number of funds on behalf of the Government, including the Marsden Fund and the Centres 
of Research Excellence Fund.
The Royal Commission on Genetic Modification – www.gmcommission.govt.nz
INTERNATIONAL LINKS
BIOTECanada – www.biotech.ca
BIOTECanada is the national organisation dedicated to promoting to Canadian citizens a 
better understanding of biotechnology. The site represents Canadian healthcare, agricultural,
food, research and other organisations involved in biotechnology.
Biotechnology and Biological Sciences Research Council – www.bbsrc.ac.uk
This council is Britain’s lead funding agency for academic research and training in the 
non-medical life sciences. The site offers news and events, bioscience research updates and
science and society discussion documents. 
Biotechnology Australia – www.biotechnology.gov.au
Biotechnology Australia was established in the 1999-2000 Commonwealth Budget. It is a 
multi-departmental government agency – responsible for co-ordinating non-regulatory
biotechnology issues for the Commonwealth Government –  and seeks to provide balanced 
and factual information on biotechnology in the Australian community.
Biotechnology Ireland – www.biotechnologyireland.com
This interactive website is maintained by BioResearch Ireland. It provides a current view of
developments in the Irish biotech sector, offering conference details, news and research papers.
European Federation of Biotechnology – www.efbweb.org
The European Federation of Biotechnology is the non-profit association of all national and
cross-national learned societies, universities, institutes, companies and individuals interested in
the promotion of biotechnology in Europe. 
OECD Biotechnology – www.oecd.org
The OECD Biotechnology website provides an overview of work currently being undertaken by
the OECD in this field. Coverage includes biotechnology and agriculture and biotechnology in
science/technology and industry together with updates and news releases.
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